All right, welcome back to a plenary session and drug development exclusive.

I'm joined by Timothy Olivier, by Alison Haslam, by Miguel Zugman, and many others from our laboratory.

We're going to talk about the top ASCO abstracts.

This is prior to ASCO. We're recording this on the Wednesday before ASCO.

Timothy has put together these slides. We're going to talk about seven abstracts that we think are worth looking into.

And even without seeing the full results, we're thinking about the questions we have,

what's going through our mind, what we're going to be looking for.

Let's get started.

All right.

These are the big ones.

We've got Laura, which is maintenance asomeridinib in stage three lung cancer.

Oh, if you like Adora, you're going to like Laura.

We have Destiny Breast 6, which is giving Trasthusemab dux tecan right up front as the initial

chemotherapy.

We have telehealth palliative care because who wouldn't want to do more things by telehealth?

We have Evoke 1, which is secetusmaev govetikin versus dosataxil and second line lung cancer.

Good old dosataxil, once again, that control arm.

It'll be that control arm for another 100 years.

Nadina, neoadjuvant, Ipenevo, melanoma.

We have transmet, which is a trial of surgery versus chemotherapy alone,

chemo plus surgery versus chemotherapy alone in colorectal cancer with liver mats that are unresectable.

And we have a proton non-furity studies. So it's a good blend here. I think we've got some

...